Science Rabbit Newsletter

A neuroscientist’s deep dive into how these medications rewire neural circuits, reshape reward pathways, and may protect against dementia.

In 2024, Harvard researchers published findings that sent shockwaves through the medical community: patients taking semaglutide (Ozempic) faced a 4 to 7-fold increased risk of sudden, irreversible vision loss from a condition called NAION¹. Within weeks, an avalanche of lawsuits were filed. Yet paradoxically, around the same time, other researchers reported something extraordinary, the same drugs appeared to reduce cravings for alcohol by 50-56% and opioid use by 40%². Welcome to the bewildering world of GLP-1 receptor agonists, where breakthrough treatments and concerning side effects collide, where social media influencers peddle “nature’s Ozempic” while the FDA seizes counterfeit drugs, and where a medication designed for diabetes might hold keys to treating Alzheimer’s disease.

As a neuroscientist, I’ve watched this pharmaceutical revolution unfold with both fascination and real concern. These drugs don’t just shrink waistlines, they fundamentally alter how our brains process reward, regulate appetite, and potentially protect against neurodegeneration. But the explosion of misinformation surrounding these medications has created a perfect storm of false hope, unnecessary fear, and dangerous self-medication. Below, I examine what these drugs actually do to your brain, backed by the latest neuroscience research through 2025.

Separating Fact from Fiction: What Science Actually Says

Before we dive into the neuroscience, let’s address the shocking amount of misinformation stampeding through social media. The misinformation surrounding GLP-1 drugs has reached crisis levels, with everyone from wellness influencers to compounding pharmacies making claims that range from merely wrong to potentially lethal.

False Claim: “Natural GLP-1 supplements work just like Ozempic”

Reality: This is perhaps the most dangerous misconception circulating online. Your body naturally produces GLP-1, a hormone that signals satiety after eating. But here’s what supplement companies won’t tell you: natural GLP-1 has a half-life of approximately 2 minutes³. Within seconds of release, an enzyme called DPP-4 degrades it into inactive fragments. Pharmaceutical GLP-1 agonists are engineered molecules designed to resist this degradation, lasting days to weeks in your system. The difference in receptor activation between natural supplements and pharmaceutical drugs is approximately 1000-fold⁴. A meta-analysis of berberine, often marketed as “nature’s Ozempic,” showed an average weight loss of 4.5 pounds⁵. Semaglutide? Around 30-35 pounds⁶.

False Claim: “These are just vanity drugs for celebrities”

Reality: While media coverage focuses on Hollywood weight loss, these medications are FDA-approved treatments for chronic diseases. The 2023 SELECT trial, involving 17,604 patients across 41 countries, demonstrated that semaglutide reduced fatal and non-fatal cardiovascular events by 20%⁷. This makes it one of the first weight-loss medications proven to save lives. As of 2025, they’re approved for type 2 diabetes, obesity, cardiovascular risk reduction, chronic kidney disease, and obstructive sleep apnea⁸.

False Claim: “You can stop taking them once you reach your goal weight”

Reality: The STEP 4 trial definitively answered this question: participants who discontinued semaglutide after 20 weeks regained a significant amount of their body weight within 52 weeks, losing two-thirds of their treatment benefit^9,10. These medications treat chronic conditions that require ongoing management, not temporary problems that can be “cured.”

False Claim: “Compounded versions from online clinics are just as good”

Reality: As of July 2025, the FDA has documented 605 adverse events from compounded semaglutide and 545 from compounded tirzepatide¹¹. Dosing errors ranged from 5 to 20 times the intended dose. The FDA found that a significant proportion of websites selling “compounded GLP-1s” were operating illegally, with some being outright scams requesting additional “customs fees”¹².

False Claim: “These drugs cause depression and suicidal thoughts”

Reality: A massive Nature Medicine study analyzing 240,618 patients found the opposite: semaglutide was associated with a 73% lower risk of suicidal ideation compared to other obesity and diabetes treatments¹³. The FDA’s 2024 safety review found no evidence of increased suicidal thoughts¹⁴. However, the complete picture remains complex, most clinical trials excluded patients with active psychiatric conditions, leaving questions about vulnerable populations unanswered.

The Neuroscience: How GLP-1 Drugs Rewire Your Brain

To understand why a diabetes medication can simultaneously affect weight, addiction, and potentially dementia, we need to explore where and how these drugs work in the brain. Unlike simple appetite suppressants, GLP-1 agonists orchestrate a complex symphony of neural changes across multiple brain systems.

Where GLP-1 Receptors Live in Your Brain

GLP-1 receptors aren’t randomly scattered throughout your brain, they’re strategically positioned in regions controlling reward, appetite, memory, and executive function¹⁵. The highest density exists in the lateral septum, a region connecting emotional and motivational circuits. But the most fascinating distributions are in:

The Reward System: In the ventral tegmental area (VTA) and nucleus accumbens (NAc), the same regions hijacked by addictive drugs; GLP-1 receptors modulate dopamine signaling. A groundbreaking Science study revealed that semaglutide suppressed dopamine-releasing neuron responses during enjoyable food consumption¹⁶. This reduced enjoyment of food in the moment may explain why patients report that food simply becomes less interesting, what many call the silencing of “food noise.”

The Hypothalamus: Within the arcuate nucleus, GLP-1 drugs simultaneously activate POMC neurons (which suppress appetite) while inhibiting NPY/AgRP neurons (which drive hunger)¹⁷. It’s like pressing the brake and releasing the accelerator simultaneously, a dual mechanism that makes these drugs uniquely powerful for appetite control.

The Hippocampus: Here’s where things get particularly intriguing for neurodegenerative diseases. GLP-1 receptors are abundant throughout the hippocampus, particularly in the dentate gyrus where new neurons are born throughout life¹⁸. Activation of these receptors increases BDNF (brain-derived neurotrophic factor) in an Alzheimer’s disease mouse model, essentially fertilizing the soil for new neuronal growth and reversing some neurodegenerative phenotypes¹⁹.

The Blood-Brain Barrier Problem (and Solution)

Here’s a critical fact that most discussions miss: not all GLP-1 drugs are created equal when it comes to brain penetration. The blood-brain barrier (BBB) is notoriously selective, and different GLP-1 agonists have vastly different abilities to cross it²⁰. The varying ability of different GLP-1 agonists to penetrate the brain directly may influence their therapeutic potential for neurological conditions beyond their metabolic effects.

The Link Between Shingles and Stroke Explained

Why are women twice as likely to get Alzheimer’s disease?

Cardio is Cognition

Neural Circuits: Beyond Simple Appetite Suppression

The true elegance of GLP-1 drugs lies not in blocking a single pathway but in modulating entire neural networks. Research has mapped the specific circuits involved:

The Gut-Brain Highway: GLP-1 neurons in the nucleus tractus solitarius (NTS) send direct projections to the VTA and nucleus accumbens, targeting reward centers²¹. When activated, they don’t eliminate pleasure, they recalibrate it. Food remains enjoyable, but the compulsive drive to seek it diminishes.

The Stress-Reward Connection: GLP-1 receptors in the amygdala and bed nucleus of the stria terminalis modulate stress responses²². This may explain why some patients report reduced anxiety around food and decreased emotional eating patterns.  

The Executive Control Network: Receptors in the prefrontal cortex influence decision-making and impulse control²³. Patients often describe making food choices that surprise them, reaching for an apple instead of cookies not through willpower but because the apple genuinely seems more appealing.

Beyond Weight Loss: The Brain Applications That Could Change Medicine

Alzheimer’s Disease: The Most Promising Frontier

The evidence for GLP-1 drugs in Alzheimer’s is moving from intriguing to compelling. A 2024 real-world study of 1.09 million patients found that semaglutide reduced Alzheimer’s risk by 40-70% compared to other diabetes medications²⁴.

The ELAD trial presented at the 2024 Alzheimer’s Association International Conference showed that liraglutide slowed cognitive decline by 18% and reduced brain shrinkage by 50% over 12 months²⁵. Two massive Phase 3 trials—EVOKE and EVOKE+—are testing semaglutide in 3,680 Alzheimer’s patients, with results expected in 2025-2026²⁶.

The mechanisms are multifaceted²⁷:

• Reduced amyloid-beta accumulation
• Decreased tau phosphorylation
• Enhanced clearance of toxic proteins
• Increased neurogenesis and synaptic plasticity
• Reduced neuroinflammation

Parkinson’s Disease: Promising Developments

The Parkinson’s data shows encouraging results across multiple trials. In April 2024, the NEJM published a French trial showing that lixisenatide improved motor scores by 3.08 points compared to placebo²⁸. A February 2025 UK trial of exenatide also demonstrated similar benefits²⁹.

The Addiction Breakthrough Nobody Expected

Perhaps the most surprising discovery involves addiction. Researchers noticed that patients on GLP-1 drugs spontaneously reported drinking less alcohol. A 2024 cohort study of 227,866 patients with alcohol use disorder found that those prescribed GLP-1 agonists had 50-56% lower rates of alcohol-related healthcare events³⁰. For opioid use, a separate analysis of 503,747 patients with opioid use disorder showed a 40% reduction in opioid overdose risk for those on GLP-1 medications³¹.

Additional observational data has emerged from unexpected sources. A 2024 analysis of social media posts from over 2,000 GLP-1 users found that 23% spontaneously reported quitting or reducing smoking, despite not using the medication for that purpose³².

The mechanism involves GLP-1 receptors in the VTA and nucleus accumbens modulating dopamine reward signals³³. Clinical trials are now underway testing these drugs for alcohol use disorder, with preliminary results showing significant efficacy.

Safety, Side Effects, and Individual Variation

The Non-Responder Mystery

Here’s a crucial fact rarely discussed: 15-20% of people don’t respond to GLP-1 drugs. Genetics plays a role. The ARRB1 gene variant (Thr370Met), carried by 6-11% of Hispanic and American Indian populations, enhances response³⁴. The GLP1R variant (Gly168Ser) reduces it. But a 2025 Nature Medicine study found that common BMI-related genetic variants explain surprisingly little of the response variation³⁵, suggesting other factors like gut microbiome, insulin sensitivity, and neural receptor density, may be more important.

The Serious Concerns

Vision Loss (NAION): The 4-7x increased risk of NAION (non-arteritic anterior ischemic optic neuropathy) reported in July 2024 represents the most serious emerging concern³⁶. NAION causes sudden, painless, irreversible vision loss. The mechanism remains unclear, and the absolute risk is still low (approximately 10 per 100,000 patient-years), but anyone with existing optic nerve problems needs careful consideration.

Gallbladder Disease: Meta-analysis shows a 37% increased risk of gallbladder problems, with a 70% increased risk of requiring gallbladder removal³⁷. The mechanism involves delayed gallbladder emptying combined with rapid weight loss.

Mental Health: Despite fears, large-scale data is reassuring. The Nature Medicine study showing 73% lower suicidal ideation risk should alleviate concerns¹³. However, case reports of depression resolving after discontinuation suggest vulnerable individuals may exist³⁸.

The Rebound Problem

Weight regain after stopping is nearly universal. The STEP 4 extension showed significant weight regain within a year⁹. This isn’t drug failure, it’s the nature of treating chronic disease. Like hypertension or diabetes, obesity requires ongoing management.

The Future: What’s Coming Next

Oral GLP-1s: The Game Changer

Needles have been a major barrier. Orforglipron, Eli Lilly’s oral GLP-1, will change that. The ATTAIN-1 trial showed significant weight loss with no food or water restrictions (unlike oral semaglutide, which requires 30-minute fasting). The ACHIEVE-3 trial proved superiority over oral semaglutide³⁹. FDA approval is expected in 2026.

Triple Agonists: Approaching Surgery Results

Retatrutide, targeting GLP-1, GIP, and glucagon receptors, achieved 24.2% weight loss in Phase 2 trials⁴⁰, approaching bariatric surgery outcomes. By adding glucagon, these drugs increase energy expenditure, potentially addressing the metabolic slowdown that plagues weight loss.

Beyond Metabolism: The Neurological Revolution

By 2026, we’ll know if GLP-1 drugs prevent Alzheimer’s. The EVOKE trials will report results, potentially marking the first disease-modifying Alzheimer’s treatment. Addiction trials are expanding rapidly, with studies in alcohol, opioid, and stimulant use disorders.

The Bottom Line: Revolution with Caveats

GLP-1 receptor agonists represent a genuine revolution in medicine, but not a magic bullet. They work by modulating fundamental brain circuits controlling reward, appetite, and potentially neuroprotection. The cardiovascular benefits are proven, the weight loss substantial, and the neurological applications promising.

But they’re not without risks. Muscle loss needs active management through protein intake and resistance training. Vision loss, while rare, is serious. The need for lifelong treatment makes cost and access critical issues; branded drug cost can be over $1k monthly, limiting access despite affecting conditions that disproportionately impact lower-income populations.

Most importantly, these drugs don’t work in isolation. The patients who succeed combine medication with lifestyle changes, addressing the complex behavioral and environmental factors driving metabolic disease. As we’ve learned from decades of treating chronic disease, pharmaceutical breakthroughs work best when integrated with comprehensive care.

The brain effects of GLP-1 drugs extend far beyond weight loss, potentially offering new treatments for addiction, neurodegeneration, and psychiatric conditions. But as with any powerful tool, understanding both capabilities and limitations is essential. The science is compelling, the potential transformative, but the story is still being written. What’s certain is that these molecules have opened a new chapter in our understanding of the intimate connection between metabolism and mind.

Dr. Andrew Bubak, PhD, MS, is a Neuroscientist and Professor of Neurology.

References

1. Hathaway JT, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Using Semaglutide. JAMA Ophthalmol. 2024;142(7):632-640.
2. Qeadan F, et al. The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis. Addiction. 2025 Feb;120(2):236-250. doi: 10.1111/add.16679. Epub 2024 Oct 16. PMID: 39415416; PMCID: PMC11707322.
3. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439.
4. Müller TD, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130.
5. Asbaghi O, Ghanbari N, Shekari M, Reiner Ž, Amirani E, Hallajzadeh J, Mirsafaei L, Asemi Z. The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials. Clin Nutr ESPEN. 2020 Aug;38:43-49. doi: 10.1016/j.clnesp.2020.04.010. Epub 2020 May 6. PMID: 32690176.
6. Bergmann NC, Davies MJ, Lingvay I, Knop FK. Semaglutide for the treatment of overweight and obesity: A review. Diabetes Obes Metab. 2023 Jan;25(1):18-35. doi: 10.1111/dom.14863. Epub 2022 Oct 18. PMID: 36254579; PMCID: PMC10092086. FDA Approvals Database. Multiple approval letters 2024-2025.
7. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. PMID: 37952131. Epic Research. Real-world weight regain after GLP-1 discontinuation. Epic Health Database Analysis. 2025.
8. Prime Therapeutics. GLP-1 Pipeline Update: May 2025. Prime Therapeutics Portal. Published May 26, 2025.
9. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414–1425. doi:10.1001/jama.2021.3224
10. Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19. PMID: 35441470; PMCID: PMC9542252.
11. U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Silver Spring, MD: U.S. Department of Health and Human Services, October 2025. Available at: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss.
12. U.S. Food and Drug Administration. FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain. Silver Spring, MD: U.S. Department of Health and Human Services, April 2025. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain.​
13. Wang W, et al. Associations of semaglutide with first-time suicidal ideation and suicide attempts. Nature Medicine. 2024;30:168-176.
14. FDA Drug Safety Communication. Update on evaluation of suicidal thoughts with GLP-1 receptor agonists. 2024.
15. Gabery S, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429.
16. Chen X, et al. Hedonic eating is controlled by dopamine neurons that oppose GLP-1R satiety. Science. 2024;383:adt0773.
17. Secher A, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473-4488.
18. During MJ, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9(9):1173-1179.
19. Bomba M, Granzotto A, Castelli V, et al. Exenatide Reverts the High-Fat-Diet-Induced Impairment of BDNF Signaling and Inflammatory Response in an Animal Model of Alzheimer’s Disease. Journal of Alzheimer’s Disease. 2019;70(3):793-810. doi:10.3233/JAD-190237
20. West J, Li M, Wong S, Le GH, Teopiz KM, Valentino K, Dri CE, McIntyre RS. Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review. Neurol Ther. 2025 Aug;14(4):1157-1166. doi: 10.1007/s40120-025-00724-y. Epub 2025 Apr 2. Erratum in: Neurol Ther. 2025 Aug;14(4):1167-1168. doi: 10.1007/s40120-025-00758-2. PMID: 40172827; PMCID: PMC12255637.
21. Alhadeff AL, et al. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology. 2012;153(2):647-658.
22. Kinzig KP, et al. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci. 2002;22(23):10470-10476.
23. Hsu TM, et al. A hippocampus to prefrontal cortex neural pathway inhibits food motivation through glucagon-like peptide-1 signaling. Mol Psychiatry.
24. Wang W, et al. Associations of semaglutide with first-time diagnosis of Alzheimer’s disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimers Dement. 2024;20(12):8661-8672.
25. Edison P, et al. Evaluation of liraglutide in the treatment of Alzheimer’s disease: Results from the ELAD study. Presented at: Alzheimer’s Association International Conference; July 28-Aug 1, 2024; Philadelphia, PA.
26. Cummings JL, Atri A, Feldman HH, Hansson O, Sano M, Knop FK, Johannsen P, León T, Scheltens P. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease. Alzheimers Res Ther. 2025 Jan 8;17(1):14. doi: 10.1186/s13195-024-01666-7. PMID: 39780249; PMCID: PMC11708093.
27. Reich N, et al. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review. Front Neurosci. 2022;16:970925.
28. Meissner WG, et al. Trial of Lixisenatide in Early Parkinson’s Disease. N Engl J Med. 2024;390:1176-1185.
29. Athauda D, et al. Exenatide once weekly versus placebo for Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2025;405:620-630.
30. Wang W, et al. Associations between glucagon-like peptide-1 receptor agonists and alcohol use disorder healthcare encounters in a cohort study. JAMA Psychiatry. 2024;81(4):372-380.
31. Qeadan F, McCunn A, Tingey B. The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis. Addiction. 2025 Feb;120(2):236-250. doi: 10.1111/add.16679. Epub 2024 Oct 16. PMID: 39415416; PMCID: PMC11707322.
32. Arillotta D, Floresta G, Papanti Pelletier GD, Guirguis A, Corkery JM, Martinotti G, Schifano F. Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach. Brain Sci. 2024 Jun 20;14(6):617. doi: 10.3390/brainsci14060617. PMID: 38928616; PMCID: PMC11202225.
33. Skibicka KP. The central GLP-1: implications for food and drug reward. Frontiers in neuroscience. 2013 Oct 14;7:181.
34. Dawed AY, et al. Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. Lancet Diabetes Endocrinol. 2023;11(1):59-69.
35. German, J., Cordioli, M., Tozzo, V. et al. Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery. Nat Med 31, 2269–2276 (2025). https://doi.org/10.1038/s41591-025-03645-3
36. Hathaway JT, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Using Semaglutide. JAMA Ophthalmol. 2024;142(7):632-640.
37. He L, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2022;182(5):513-519.
38. Marzano L, et al. Case Report: Semaglutide-associated depression: a report of two cases. Front Psychiatry. 2023;14:1238353.
39. Lilly’s oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial. Eli Lilly and Company. September 17, 2025.  https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-superior-oral-semaglutide-head
40. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389:514-526.